Source comparison
Melanotan-1 vs Melanotan-2: Receptor Binding & Side Effect Profile
Receptor promiscuity determines everything. Melanotan-2 binds all five melanocortin receptor subtypes (MC1R through MC5R) with roughly equal affinity, which is why it produces both tanning and a cascade of off-target effects: reduced appetite through MC4R acti
This comparison does not assign a generated winner or score.
- Receptor promiscuity determines everything. Melanotan-2 binds all five melanocortin receptor subtypes (MC1R through MC5R) with roughly equal affinity, which is why it produces both tanning and a cascade of off-target effects: reduced appetite through MC4R activation in the hypothalamus, increased erectile function through MC3R/MC4R in the central nervous system, elevated blood pressure, and nausea from gastric MC receptor activation. MT-1's selectivity for MC1R means these effects are either absent or drastically reduced. The JAMA Dermatology trial found no significant difference in nausea rates between afamelanotide and placebo groups.
- The practical implication: Melanotan-1 allows pigmentation without the spontaneous sexual responses, appetite suppression, or cardiovascular strain documented with MT-2. This selectivity comes at a cost. MT-1 requires higher dosing (16mg every 8–10 weeks in clinical protocols vs 0.5–1mg daily for MT-2) and takes longer to reach visible pigmentation. The trade-off matters most for users prioritising photoprotection over rapid cosmetic darkening or those with cardiovascular contraindications.
- Pharmacological half-life also differs: MT-1's half-life is approximately 33 minutes after subcutaneous injection, while MT-2 persists closer to 1–2 hours. Despite shorter plasma presence, MT-1's receptor binding initiates a melanogenesis cascade lasting 7–10 days per dose, which is why clinical protocols space injections weeks apart rather than daily.